Sirtuin 2通过去乙酰化HNF4α预防肝脏脂肪变性和代谢紊乱
该研究整合人类和啮齿类NAFLD样本的基因组数据,发现SIRT2在晚期NAFLD患者和高脂饮食诱导的NAFLD小鼠肝脏中显著下调。在ob/ob或HFD喂养小鼠中恢复肝脏SIRT2表达可缓解胰岛素抵抗、肝脏脂肪变性和系统性炎症,而肝脏特异性敲除SIRT2则加重代谢功能障碍。机制上,SIRT2通过结合并去乙酰化HNF4α的赖氨酸458位点稳定HNF4α蛋白,SIRT2-HNF4α通路可能是NAFLD治疗的有前景策略。
要点
- SIRT2在晚期NAFLD患者和HFD诱导的NAFLD小鼠肝脏中显著下调
- 恢复肝脏SIRT2表达可缓解胰岛素抵抗、肝脏脂肪变性和系统性炎症
- SIRT2通过去乙酰化HNF4α K458位点稳定HNF4α蛋白发挥保护作用
核心结论
- SIRT2是NAFLD及相关代谢紊乱的关键负调控因子,靶向SIRT2-HNF4α通路可能是NAFLD治疗的有前景策略。
研究设计与样本
- 研究整合Gene Expression Omnibus中已发表的人类和啮齿类NAFLD样本基因组数据,并在ob/ob小鼠、HFD喂养小鼠、HFD喂养的C57BL/6J小鼠及棕榈酸处理的HepG2细胞中进行实验验证。
主要发现
- SIRT2在晚期NAFLD患者肝脏和HFD诱导的NAFLD小鼠肝脏中显著下调。
- SIRT2在肥胖(ob/ob)小鼠和棕榈酸处理的HepG2细胞中明显减少。
- 在ob/ob或HFD喂养小鼠中恢复肝脏SIRT2表达可大幅缓解胰岛素抵抗、肝脏脂肪变性和系统性炎症。
- 肝脏特异性敲除SIRT2加剧HFD喂养C57BL/6J小鼠的代谢功能障碍。
- SIRT2通过结合并去乙酰化HNF4α的赖氨酸458位点稳定HNF4α蛋白,且SIRT2-HNF4α相互作用在体内和体外均为SIRT2功能所必需。
临床怎么用
- SIRT2-HNF4α通路可作为NAFLD治疗的潜在靶点,但尚需进一步临床转化研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Sirtuin 2 (SIRT2), an NAD+ -dependent deacetylase, is involved in various cellular processes regulating metabolic homeostasis and inflammatory responses; however, its role in hepatic steatosis and related metabolic disorders is unknown. APPROACH AND RESULTS: Integrating the published genomic data on NAFLD samples from humans and rodents available in the Gene Expression Omnibus, we found that SIRT2 was significantly down-regulated in livers from patients with advanced NAFLD and high-fat diet (HFD)-induced NAFLD mice. This study further revealed that SIRT2 was markedly decreased in obese (ob/ob) mice and in palmitate-treated HepG2 cells. Restoration of hepatic SIRT2 expression in ob/ob or HFD-fed mice largely alleviated insulin resistance, hepatic steatosis, and systematic inflammation, whereas SIRT2 liver-specific ablation exacerbated these metabolic dysfunctions in HFD-fed C57BL/6J mice. Mechanistically, SIRT2 stabilized the hepatocyte nuclear factor 4α (HNF4α) protein by binding to and deacetylating HNF4α on lysine 458. Furthermore, HNF4α was sufficient to mediate SIRT2 function, and SIRT2-HNF4α interaction was required for SIRT2 function both in vivo and in vitro. CONCLUSIONS: Collectively, the present study provided evidence that SIRT2 functions as a crucial negative regulator in NAFLD and related metabolic disorders and that targeting the SIRT2-HNF4α pathway may be a promising strategy for NAFLD treatment.
引用
- Ren H, Hu F, Wang D, et al. Sirtuin 2 Prevents Liver Steatosis and Metabolic Disorders by Deacetylation of Hepatocyte Nuclear Factor 4α. Hepatology. 2021. PMID: 33636024. doi:10.1002/hep.31773
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。